Dermata Therapeutics Q1 2026: cash $6.9M; R&D spend down to $0.4M; DTC skincare launch planned mid-2026

Dermata Therapeutics, Inc.

Cash and cash equivalents $6.9M as of Mar 31, 2026, down from $7.5M at Dec 31, 2025; net ATM proceeds of $2.0M.
R&D expenses fell to $0.4M from $1.3M YoY, reflecting reduced clinical spending; SG&A rose to $1.5M from $1.1M.
Announced Tome skincare brand for DTC; first product (Foundational Treatment) expected to launch mid-2026.
Hired Kyra Peckaitis as VP of Marketing to lead Tome brand; cash expected to fund operations into Q1 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dermata Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 13, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the quarter ended March 31, 2026, and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-022710

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.